(Q35824821)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15230850%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

review article

1 reference

title

Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15230850%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

1 reference

George Papatheodoridis

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15230850%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Cholongitas E

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15230850%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

1 July 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15230850%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15230850%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15230850%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15230850%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

287-296

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15230850%20AND%20SRC:MED&resulttype=core&format=json

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Alcohol use and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Treatment of recurrent hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Retreatment of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

New therapeutic strategies for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Monitoring of viral levels during therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Advances in hepatitis C: what is coming in the next 5 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Design of selective eglin inhibitors of HCV NS3 proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Hepatitis C virus protease inhibitors: current progress and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Persistence of YMDD variants after withdrawal of Lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Hepatitis B viral genotypes and lamivudine resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Antiviral effects of antisense RNA on hepatitis C virus RNA translation and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Future therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Ribozyme gene therapy for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Immunopathogenesis of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Long-term course of interferon-treated chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00522.X

10.1111/J.1365-2893.2004.00522.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15230850%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference